Soleno Therapeutics Sued for Securities Law Violations

DJS Law Group Encourages Investors to Discuss Their Rights

Mar. 20, 2026 at 8:49am

Got story updates? Submit your updates here. ›

The DJS Law Group has filed a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) for alleged violations of federal securities laws. The lawsuit claims Soleno made false and misleading statements about the safety and commercial viability of its drug candidate DCCR during a class period from March 26, 2025 to November 4, 2025. Shareholders who purchased Soleno stock during this time are encouraged to contact the law firm about potentially serving as lead plaintiffs.

Why it matters

This lawsuit alleges Soleno misled investors about the prospects of its key drug in development, which could have significant financial implications for the company and impact shareholder value. Securities fraud cases like this one aim to hold public companies accountable for providing accurate information to the market.

The details

According to the complaint, Soleno's Phase 3 clinical trial of its DCCR drug candidate revealed safety concerns that the company then downplayed, making its public statements false and misleading. The lawsuit claims DCCR also suffered from diminished commercial viability, contradicting Soleno's public statements.

  • The class period for the lawsuit is March 26, 2025 to November 4, 2025.
  • The deadline for shareholders to join the case is May 5, 2026.

The players

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on developing and commercializing therapies for patients with rare diseases.

DJS Law Group

A law firm specializing in securities class actions, corporate governance litigation, and M&A appraisals, representing large hedge funds and alternative asset managers.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on May 5, 2026 whether to allow the case to proceed as a class action lawsuit, which would enable more shareholders to join and potentially recover losses.

The takeaway

This case highlights the importance of pharmaceutical companies providing accurate information to investors about the status and prospects of their drug candidates in development. Shareholders will be watching closely to see if Soleno is held accountable for any alleged securities law violations.